Cedars-Sinai Cancer in Los Angeles serves one of the most diverse regions globally. Ranked No. 7 for cancer by U.S. News & World Report 2020-2021, the center’s clinicians are committed to providing compassionate, state-of-the-art care, while its scientists are carrying out the latest translational research and groundbreaking advances. The cancer enterprise includes the Samuel Oschin Comprehensive Cancer Institute, The Angeles Clinic and Research Institute, Tower Hematology Oncology Medical Group, Torrance Memorial Hunt Cancer Center and Cedars-Sinai Tarzana.
Breakthroughs in Imaging Modalities for Prostate Cancer
March 3rd 2023Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.
BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance
Bobbie J. Rimel, MD, discusses how PARP inhibitors are deployed across different treatment settings of ovarian cancer, the recent market withdrawal of PARP inhibitors in later-line indications, and ongoing research efforts at Cedars-Sinai Medical Center for patients with ovarian cancer.